Lu AA41063 is a selective adenosine A2A receptor antagonist. Structurally, it is a non-xanthine.
The affinities (Ki) of the drug for the human adenosine receptors are 5.9 nM for the adenosine A2A receptor, 410 nM for the adenosine A1 receptor (69-fold lower than for the A2A receptor), 260 nM for the adenosine A2B receptor (44-fold lower than for the A2A receptor), and >10,000 nM for the adenosine A3 receptor (>1,695-fold lower than for the A2A receptor).
Lu AA41063 was first described in the scientific literature by 2014.
Lu AA47070, a water-soluble phosphate ester prodrug of Lu AA41063, is orally active and was under development for the treatment of Parkinson's disease but was discontinued. In addition to its antiparkinsonian-like effects, Lu AA47070 reverses motivational deficits in animals and hence shows pro-motivational effects.
References
